

Remarks

Claims 17 and 27 are pending in this application following amendments presented in this paper. Without prejudice or disclaimer, and in consideration of the new U.S.P.T.O. Rules, 37 C.F.R. 1.75(b), Examination of Claims, Claims 3-6, 9-12 and 24-26 are cancelled in this paper. Claims 1, 2, 7, 8, 13-16, 18 (both occurrences) and 19-23 were previously cancelled.

Solely for the convenience of examination, Applicants contend the compounds of Claim 17, correspond, in order, to Examples 1-18, 20 and 19.

Applicants contend the amendments presented by this paper more clearly define the subject matter of the present invention. No new matter is believed added by any of the amendments presented.

Applicants respectfully request favorable consideration of this application and their invention as claimed.

Respectfully submitted,

/John C. Demeter/

John C. Demeter
Attorney for Applicants
Registration No. 30,167
Phone: 317-276-3785

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

September 28, 2007